Overview

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Status:
Terminated

Trial end date:
2019-05-07

Target enrollment:

Participant gender:

Summary

Clinical trial with a pharmaceutical specialty in a new combination. Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with multiple treatment-resistant or relapsing myeloma who have received at least two previous treatments, including lenalidomide and bortezomib, and who have experienced a disease progression in the last treatment. The combination of Pomalidomide with Cyclophosphamide at metronomic doses (Very low doses) and Dexamethasone is tested in this clinical situation.

Phase:

Phase 2

Details

Lead Sponsor:

Maimónides Biomedical Research Institute of Córdoba

Treatments:

BB 1101
Bortezomib
Cyclophosphamide
Dexamethasone
Dexamethasone acetate
Lenalidomide
Pomalidomide
Thalidomide